Alnylam Pharmaceuticals | ALNY - Operating Expenses


Alnylam Pharmaceuticals reported $1.11B in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.12M 2.55M Jun/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
Amgen USD 11.69B 6.9B Jun/2026
Arrowhead Research USD 245.35M 30.35M Jun/2026
BioCryst Pharmaceuticals USD 119.78M 673.63M Jun/2026
BioMarin Pharmaceutical USD 6.32B 5.69B Jun/2026
Incyte USD 5.64B 4.67B Sep/2026
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
Moderna USD 960M 817M Jun/2026
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
Novartis USD 9.29B 507M Mar/2026
PTC Therapeutics USD 211.54M 15.12M Jun/2026
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 8.98B 1.73B Mar/2026
Sarepta Therapeutics USD 387.96M 15.59M Jun/2026
Takeda JPY 981.78B 36.71B Sep/2026
Tectonic Therapeutic USD 27.3M 5.78M Mar/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026
Xencor USD 87.82M 5.44M Jun/2026